Suppression of atrial fibrillation with mexiletine pharmacotherapy in a young woman with type 1 long QT syndrome

Heart Rhythm

Volumn 5, Issue 3, 2008, Pages 472-474

  El Yaman, Malek ^a   Perry, James ^b   Makielski, Jonathan C ^c   Ackerman, Michael J ^a,d  

^a MAYO CLINIC   (United States)

^b Children's Heart Clinic   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

Atrial arrhythmia; Atrial fibrillation; Class I antiarrhythmic; Long QT syndrome; Mexiletine; Sodium current

Indexed keywords

ATENOLOL; MEXILETINE; POTASSIUM; PROPRANOLOL; WARFARIN;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; CASE REPORT; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HEART ATRIUM FIBRILLATION; HEART ATRIUM HYPERTROPHY; HEART PALPITATION; HOLTER MONITORING; HUMAN; LONG QT SYNDROME; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RISK REDUCTION; SINUS RHYTHM;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHILD; FEMALE; HUMANS; LONG QT SYNDROME; MEXILETINE;

EID: 39749094942     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2007.10.029     Document Type: Article

References (17)

1. Ackerman M.J. Cardiac channelopathies: it's in the genes. Nat Med 10 (2004) 463-464
2. Tester D.J., Will M.L., Haglund C.M., et al. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol 47 (2006) 764-768
3. Kirchhof P., Eckardt L., Monnig G., et al. A patient with "atrial torsades de pointes.". J Cardiovasc Electrophysiol 11 (2000) 806-811
4. Kirchhof P., Eckardt L., Franz M.R., et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol 14 (2003) 1027-1033
5. Satoh T., and Zipes D.P. Cesium-induced atrial tachycardia degenerating into atrial fibrillation in dogs: atrial torsades de pointes?. J Cardiovasc Electrophysiol 9 (1998) 970-975
6. Monk J.P., and Brogden R.N. Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. [published erratum appears in Drugs 1991;41:377]. Drugs 40 (1990) 374-411
7. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 92 (1995) 3381-3386
8. Garcia-Touchard A., Somers V.K., Kara T., et al. Ventricular ectopy during REM sleep: implications for nocturnal sudden cardiac death. Nat Clin Pract Cardiovasc Med 4 (2007) 284-288
9. Johnson J.N., Haglund C.M., Tester D.J., et al. Prevalence of early onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 4 (2007) S189
10. Dudel J., Peper K., Rudel R., et al. Effect of tetrodotoxin on membrane currents in mammalian cardiac fibres. Nature 213 (1967) 296-297
11. Colatsky T.J. Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. An effect on steady state sodium currents?. Circ Res 50 (1982) 17-27
12. Wasserstrom J.A., and Salata J.J. Basis for tetrodotoxin and lidocaine effects on action potentials in dog ventricular myocytes. Am J Physiol 254 (1988) H1157-H1166
13. Kiyosue T., and Arita M. Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes. Circ Res 64 (1989) 389-397
14. Sakmann B.F., Spindler A.J., Bryant S.M., et al. Distribution of a persistent sodium current across the ventricular wall in guinea pigs. Circ Res 87 (2000) 910-914
15. Sicouri S., Antzelevitch D., Heilmann C., et al. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome. J Cardiovasc Electrophysiol 8 (1997) 1280-1290
16. Inoue D., Shirayama T., Omori I., et al. Mexiletine for paroxysmal atrial fibrillation. Chest 94 (1988) 1317
17. Rona G. Treatment of atrial fibrillation with mexiletine in Wolff-Parkinson-White syndrome. Z Gesamte Inn Med 41 (1986) 355-358